This is Warren
We believe innovation starts when we stop to listen.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Behind the science
Discover how we're getting ahead
AI and ML power better predictions for patient impact
Digital twin: using advanced technology to accelerate vaccine development
‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
Combining genetics and tech to double success rates
Getting ahead of infectious diseases with advanced technology
Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease
Fresh insights could finally help us tackle RSV
The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
Our culture guides our people to do the right thing and act on any concerns they have.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
We announced our full year and fourth quarter 2022 results on Wednesday 1 February
GSK on social
#News for #Investors and #Media Today we’ve entered into an exclusive licence agreement with @scynexis. This agreement complements GSK’s infectious diseases portfolio and builds on our commitment to get ahead of AMR. Find out more: gsk.to/3zh3XY2Twitter @GSK Mar 30
#News for #Investors and #Media: Today @ViiVHC, our specialist HIV company, have announced progress in their commitment to voluntary licencing for populations with unmet needs. Find out more: gsk.comTwitter @GSK Mar 30
Scientists are turning to an array of novel approaches to try to prevent life-threatening diseases – including vaccine technologies like MAPS. gsk.to/40qx8UKTwitter @GSK Mar 29
Thank you, @IMFmyeloma, for leading another meaningful #MyelomaActionMonth! 🩸❤️ We’re inspired by those who shared their#MYelomaSTORYY and proud to support this community alongside dedicated advocacy partners like@LLSusaa,@theMMRFF and@HealthTreee.Twitter @GSK Mar 28
#News for #Investors and #Media: today at #SGOmtg, we shared promising data from our #cancer research programmes. Learn more.Twitter @GSK Mar 27
Meet our 2023 #GSKIMPACTUK Award winner @Brthcompanions, supporting and empowering women facing inequality and disadvantage during pregnancy, birth and early motherhood. Learn more here 👇birthcompanions.org.ukKMTwitter @GSK Mar 25
Meet our 2023 #GSKIMPACTUK Award winner @AuroraNewDawn, supporting victims and survivors of domestic abuse, sexual violence and stalking. Want to know more? 👉aurorand.org.ukVETwitter @GSK Mar 25
#ICYMI: @RareRevolutionM published an issue focused on people impacted by #myelofibrosis. Hear from Jenny, who shares her inspiring story as she navigates living with a rare #bloodcancer.Twitter @GSK Mar 24
Our journey to the centre of the human genome is not a solo mission. With innovative partners by our side, our supercharged #AI team is exploring the edges of humankind — inside and out. Join us! #AheadTogether #ArtificialIntelligence #GSKOnyxTwitter @GSK Mar 23
We partner with the #HIV community to develop medicines that fit into people’s lives. Find out how we’re getting ahead of HIV together in the @FT gsk.to/FTHIVORGTwitter @GSK Mar 22